Status:
COMPLETED
Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)
Lead Sponsor:
Obafemi Awolowo University Teaching Hospital
Collaborating Sponsors:
University Hospital Birmingham NHS Foundation Trust
Cures Within Reach
Conditions:
Tuberculosis, Pulmonary
Tuberculosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally, with more than 10 million new cases and over 2 million deaths annually. Developing ...
Detailed Description
INTRODUCTION Tuberculosis is a chronic disease responsible for most deaths from infectious disease with an estimated I0 million cases and close to 2million deaths globally. 1 Despite the availability ...
Eligibility Criteria
Inclusion
- Newly diagnosed, uncomplicated, drug-susceptible pulmonary TB
- Sputum Smear, culture or GenXpert result positive for pulmonary TB
- Ability to provide written, informed consent prior to trial initiation
- Male or and non pregnant female participants between 18 and 65 years of age
- Body mass index 16.0 and 32.0 kg/m2
- Ability to produce an adequate volume of sputum (approximately 10 -15mL or more estimated overnight production).
Exclusion
Key Trial Info
Start Date :
January 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04721795
Start Date
January 19 2021
End Date
June 30 2022
Last Update
December 8 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Obafemi Awolowo University Teaching Hospitals Complex
Ile-Ife, Osun State, Nigeria
2
Birmingham Heartlands Hospital
Birmingham, United Kingdom